Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016.
asbestos
malignant pleural mesothelioma
mesothelioma
national cancer database and seer analyses
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
21 Apr 2021
21 Apr 2021
Historique:
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
28
5
2021
Statut:
epublish
Résumé
Introduction Pleural mesothelioma constitutes about 80% of all mesotheliomas. The peak incidence of malignant mesothelioma estimated using the cancer registries was in early 1990 to 2000 in the United States. The disease is primarily associated with asbestos exposure. The latency period between asbestos exposure and the development of malignant pleural mesothelioma (MPM) can range anywhere from 15 to 60 years. Asbestos exposure was peaked during the industrial revolution and World War II due to military and shipyard exposures. It is often difficult for the pathologist to distinguish different histological subtypes; due to the disease's rarity and the inadequate tissue sample obtained. There is no available data on the difference in epidemiology of different subtypes of MPM. Surveillance Epidemiology and End Results (SEER), cancer incidence data include population-based registries covering approximately 34.6% of the U.S. population. Here in our study, we analyze malignant pleural mesothelioma epidemiology in the United States, emphasizing different histological subtypes. Methods SEER data from 2000 to 2016 was used in our study. The primary site of cancer is selected as pleura, and malignant behavior only is selected as the filter. Data were analyzed using the SEER stat program. Overall epidemiology of MPM and epidemiology of epithelioid, fibrous, and biphasic histological subtypes were analyzed separately. We used annual percentage change (APC) to evaluate the trend in the epidemiology of MPM. Results summary A total of 11,857 cases of MPM were included in the primary cohort from the SEER 18 registry from 2000 to 2016. The total prevalence of MPM was highest in 2009 and was lowest in 2016. The APC in MPM incidence during this period is -2.0. After removing 5,989 cases with non-specified histology during the same period, the APC for each histological type is -0.7 for fibrous type, 1.8 for epithelioid type, and 2.9 for biphasic type. Out of 17 regional registries included in the study, the greatest statistically significant change in APC was seen in the Hawaiian registry -4.1. In contrast, the lowest statistically significant difference was seen in Seattle (Puget Sound) registry -1.7. The APC in the incidence of MPM among males during the study period was -2.4 while that of females was -0.9. The Iowa registry showed a statistically significant increase in APC of the epithelioid malignant mesothelioma with a statistically insignificant reduction in the overall MPM APC. Conclusion The overall incidence of MPM in the United States is declining, while the data showed an increase in the incidence of epithelioid and biphasic histological subtypes. The authors believe that these conflicting results can be attributed to improved histological diagnosis and improved biopsy techniques.
Identifiants
pubmed: 34040906
doi: 10.7759/cureus.14605
pmc: PMC8139608
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e14605Informations de copyright
Copyright © 2021, Thomas et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Surg Res. 2015 Jun 1;196(1):23-32
pubmed: 25791825
Br J Ind Med. 1984 Nov;41(4):514-7
pubmed: 6498114
Eur J Cancer Prev. 1997 Apr;6(2):162-6
pubmed: 9237066
Arch Pathol Lab Med. 2018 Jun;142(6):747-752
pubmed: 29509030
Am J Respir Cell Mol Biol. 2010 Feb;42(2):131-2
pubmed: 20068226
Am J Epidemiol. 1997 Feb 1;145(3):211-8
pubmed: 9012593
Cancer. 1973 Apr;31(4):869-76
pubmed: 4706052
J Toxicol Environ Health B Crit Rev. 2016;19(5-6):250-265
pubmed: 27705549
Br J Cancer. 2005 Feb 14;92(3):587-93
pubmed: 15668716
N Engl J Med. 1972 Sep 14;287(11):570-1
pubmed: 5050439
Mod Pathol. 2012 Jul;25(7):1011-22
pubmed: 22388762
J Clin Pathol. 2017 Feb;70(2):179-182
pubmed: 27798081
Curr Opin Oncol. 1991 Apr;3(2):328-34
pubmed: 2069994
Cancer. 2007 Apr 1;109(7):1432-8
pubmed: 17315168
Pathol Res Pract. 2016 Oct;212(10):886-892
pubmed: 27485167
J Thorac Oncol. 2016 Feb;11(2):142-54
pubmed: 26811225
J Thorac Oncol. 2012 Nov;7(11):1631-9
pubmed: 23070243
Lancet Oncol. 2009 May;10(5):453-4
pubmed: 19418618
IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt C):11-465
pubmed: 23189751